Chemotherapy Induced Peripheral Neuropathy Treatment

Chemotherapy Induced Peripheral Neuropathy Treatment Comprehensive Study by Type (APX-3330, BR-297, Cannabidiol, Dimiracetam, Others), Application (Platinum Agents, Taxanes, Vinca Alkaloids, Others) Players and Region - Global Market Outlook to 2029

Chemotherapy Induced Peripheral Neuropathy Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Chemotherapy Induced Peripheral Neuropathy Treatment
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the majorly prevailed adverse effects of numerous cancer treatments, including platinum agents, taxanes, and vinca alkaloids. According to the Physicians' Education Resource, there are a number of methods available to assess CIPN's subjective and objective measures. Some of the subjective measures include the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale and patient-reported outcome measures, on the other hand, the objective measures include a physical examination and neurophysiological testing.

AttributesDetails
Study Period2018-2029
Base Year2023
High Growth MarketAsia-Pacific
UnitValue (USD Million)


The competitive landscape in Chemotherapy Induced Peripheral Neuropathy Treatment. With ongoing research and development, we can expect to see more effective and personalized treatment options emerge in the future, offering hope to millions of patients suffering from this debilitating side effect. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Chemotherapy Induced Peripheral Neuropathy Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Achelios Therapeutics Inc (United States), Advinus Therapeutics Limited (India), Apollo Endosurgery Inc (United States), Aptinyx Inc (United States), Asahi Kasei Pharma Corp (Japan), Can-Fite BioPharma Ltd (Israil), Regenacy Pharmaceuticals, LLC (United States), MAKScientific (United States) and Metys Pharmaceuticals AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Nemus Bioscience (United States), PledPharma (Sweden), Sova Pharmaceuticals, Inc. (United States, DermaXon LLC (United States), Immune Pharmaceuticals Inc. (United States) and Kineta, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Chemotherapy Induced Peripheral Neuropathy Treatment market by Type (APX-3330, BR-297, Cannabidiol, Dimiracetam and Others), Application (Platinum Agents, Taxanes, Vinca Alkaloids and Others) and Region.



On the basis of geography, the market of Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement.

Influencing Trend:
Increasing Demand for Dose Reduction or Discontinuation of Treatment and Continues Technological Advancements in Developing Chemotherapy Processes

Market Growth Drivers:
Increasing Prevalence of Cancer Caused Patients across the Global Market and Increasing Demand for Platinums, Taxanes, Epothilones, Vinca Alkaloids, and Newer Agents

Challenges:
Availability of Numerous Preferences for the Cancer Treatment Options might Stagnate the Business Growth

Restraints:
Measurement Complexities in Measuring the Performance Clinical Trials and Stringent Government Regulations in Developing Peripheral Neuropathy Treatments

Opportunities:
Upsurging Healthcare Infrastructure across the Developing Economies and Increasing Research and Development Investments with Encourage Service Advancements

Market Leaders and their expansionary development strategies
In August 2023, Pharmaceutical companies and patient advocacy groups has partnered Pharmaceutical companies are increasingly partnering with patient advocacy groups to develop and test new treatments for CIPN.
In May 2023, the FDA approved the first cannabis-based drug for the treatment of CIPN, Syndros. Cannabis-Based Therapies There is growing interest in the use of cannabis and cannabinoids for the treatment of CIPN. Several clinical trials are currently underway to investigate the efficacy of these therapies.


Key Target Audience
Chemotherapy-Induced Peripheral Neuropathy Treatment Providers, Chemotherapy Equipment Providers, Chemotherapy Equipment Manufacturers, Chemotherapy Distributors and Suppliers, Research and Development Institutes, Government Agencies, Healthcare Industry Associations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • APX-3330
  • BR-297
  • Cannabidiol
  • Dimiracetam
  • Others
By Application
  • Platinum Agents
  • Taxanes
  • Vinca Alkaloids
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Cancer Caused Patients across the Global Market
      • 3.2.2. Increasing Demand for Platinums, Taxanes, Epothilones, Vinca Alkaloids, and Newer Agents
    • 3.3. Market Challenges
      • 3.3.1. Availability of Numerous Preferences for the Cancer Treatment Options might Stagnate the Business Growth
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand for Dose Reduction or Discontinuation of Treatment
      • 3.4.2. Continues Technological Advancements in Developing Chemotherapy Processes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment (Value)
      • 5.2.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment by: Type (Value)
        • 5.2.1.1. APX-3330
        • 5.2.1.2. BR-297
        • 5.2.1.3. Cannabidiol
        • 5.2.1.4. Dimiracetam
        • 5.2.1.5. Others
      • 5.2.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment by: Application (Value)
        • 5.2.2.1. Platinum Agents
        • 5.2.2.2. Taxanes
        • 5.2.2.3. Vinca Alkaloids
        • 5.2.2.4. Others
      • 5.2.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Chemotherapy Induced Peripheral Neuropathy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Achelios Therapeutics Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Advinus Therapeutics Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Apollo Endosurgery Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aptinyx Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Asahi Kasei Pharma Corp (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Can-Fite BioPharma Ltd (Israil)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Regenacy Pharmaceuticals, LLC (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MAKScientific (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Metys Pharmaceuticals AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale, by Type, Application and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment (Value)
      • 7.2.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment by: Type (Value)
        • 7.2.1.1. APX-3330
        • 7.2.1.2. BR-297
        • 7.2.1.3. Cannabidiol
        • 7.2.1.4. Dimiracetam
        • 7.2.1.5. Others
      • 7.2.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment by: Application (Value)
        • 7.2.2.1. Platinum Agents
        • 7.2.2.2. Taxanes
        • 7.2.2.3. Vinca Alkaloids
        • 7.2.2.4. Others
      • 7.2.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chemotherapy Induced Peripheral Neuropathy Treatment: by Type(USD Million)
  • Table 2. Chemotherapy Induced Peripheral Neuropathy Treatment APX-3330 , by Region USD Million (2018-2023)
  • Table 3. Chemotherapy Induced Peripheral Neuropathy Treatment BR-297 , by Region USD Million (2018-2023)
  • Table 4. Chemotherapy Induced Peripheral Neuropathy Treatment Cannabidiol , by Region USD Million (2018-2023)
  • Table 5. Chemotherapy Induced Peripheral Neuropathy Treatment Dimiracetam , by Region USD Million (2018-2023)
  • Table 6. Chemotherapy Induced Peripheral Neuropathy Treatment Others , by Region USD Million (2018-2023)
  • Table 7. Chemotherapy Induced Peripheral Neuropathy Treatment: by Application(USD Million)
  • Table 8. Chemotherapy Induced Peripheral Neuropathy Treatment Platinum Agents , by Region USD Million (2018-2023)
  • Table 9. Chemotherapy Induced Peripheral Neuropathy Treatment Taxanes , by Region USD Million (2018-2023)
  • Table 10. Chemotherapy Induced Peripheral Neuropathy Treatment Vinca Alkaloids , by Region USD Million (2018-2023)
  • Table 11. Chemotherapy Induced Peripheral Neuropathy Treatment Others , by Region USD Million (2018-2023)
  • Table 12. South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2018-2023)
  • Table 13. South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 14. South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 15. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 16. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 17. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 18. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 19. Rest of South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 20. Rest of South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 21. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2018-2023)
  • Table 22. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 23. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 24. China Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 25. China Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 26. Japan Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 27. Japan Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 28. India Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 29. India Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 30. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 31. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 32. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 33. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 34. Australia Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 35. Australia Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 38. Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2018-2023)
  • Table 39. Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 40. Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 41. Germany Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 42. Germany Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 43. France Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 44. France Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 45. Italy Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 46. Italy Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 47. United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 48. United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 49. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 50. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 51. Rest of Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 52. Rest of Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 53. MEA Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2018-2023)
  • Table 54. MEA Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 55. MEA Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 56. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 57. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 58. Africa Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 59. Africa Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 60. North America Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2018-2023)
  • Table 61. North America Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 62. North America Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 63. United States Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 64. United States Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 65. Canada Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 66. Canada Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 67. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2018-2023)
  • Table 68. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2018-2023)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Chemotherapy Induced Peripheral Neuropathy Treatment: by Type(USD Million)
  • Table 79. Chemotherapy Induced Peripheral Neuropathy Treatment APX-3330 , by Region USD Million (2024-2029)
  • Table 80. Chemotherapy Induced Peripheral Neuropathy Treatment BR-297 , by Region USD Million (2024-2029)
  • Table 81. Chemotherapy Induced Peripheral Neuropathy Treatment Cannabidiol , by Region USD Million (2024-2029)
  • Table 82. Chemotherapy Induced Peripheral Neuropathy Treatment Dimiracetam , by Region USD Million (2024-2029)
  • Table 83. Chemotherapy Induced Peripheral Neuropathy Treatment Others , by Region USD Million (2024-2029)
  • Table 84. Chemotherapy Induced Peripheral Neuropathy Treatment: by Application(USD Million)
  • Table 85. Chemotherapy Induced Peripheral Neuropathy Treatment Platinum Agents , by Region USD Million (2024-2029)
  • Table 86. Chemotherapy Induced Peripheral Neuropathy Treatment Taxanes , by Region USD Million (2024-2029)
  • Table 87. Chemotherapy Induced Peripheral Neuropathy Treatment Vinca Alkaloids , by Region USD Million (2024-2029)
  • Table 88. Chemotherapy Induced Peripheral Neuropathy Treatment Others , by Region USD Million (2024-2029)
  • Table 89. South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2024-2029)
  • Table 90. South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 91. South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 92. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 93. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 94. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 95. Argentina Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 96. Rest of South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 97. Rest of South America Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 98. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2024-2029)
  • Table 99. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 100. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 101. China Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 102. China Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 103. Japan Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 104. Japan Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 105. India Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 106. India Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 107. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 108. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 109. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 110. Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 111. Australia Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 112. Australia Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 113. Rest of Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 114. Rest of Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 115. Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2024-2029)
  • Table 116. Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 117. Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 118. Germany Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 119. Germany Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 120. France Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 121. France Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 122. Italy Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 123. Italy Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 124. United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 125. United Kingdom Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 126. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 127. Netherlands Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 128. Rest of Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 129. Rest of Europe Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 130. MEA Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2024-2029)
  • Table 131. MEA Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 132. MEA Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 133. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 134. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 135. Africa Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 136. Africa Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 137. North America Chemotherapy Induced Peripheral Neuropathy Treatment, by Country USD Million (2024-2029)
  • Table 138. North America Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 139. North America Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 140. United States Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 141. United States Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 142. Canada Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 143. Canada Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 144. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment, by Type USD Million (2024-2029)
  • Table 145. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment, by Application USD Million (2024-2029)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment: by Application USD Million (2018-2023)
  • Figure 6. South America Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 7. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 8. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 9. MEA Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 10. North America Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment share by Players 2023 (%)
  • Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment share by Players (Top 3) 2023(%)
  • Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Achelios Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 16. Achelios Therapeutics Inc (United States) Revenue: by Geography 2023
  • Figure 17. Advinus Therapeutics Limited (India) Revenue, Net Income and Gross profit
  • Figure 18. Advinus Therapeutics Limited (India) Revenue: by Geography 2023
  • Figure 19. Apollo Endosurgery Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Apollo Endosurgery Inc (United States) Revenue: by Geography 2023
  • Figure 21. Aptinyx Inc (United States) Revenue, Net Income and Gross profit
  • Figure 22. Aptinyx Inc (United States) Revenue: by Geography 2023
  • Figure 23. Asahi Kasei Pharma Corp (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Asahi Kasei Pharma Corp (Japan) Revenue: by Geography 2023
  • Figure 25. Can-Fite BioPharma Ltd (Israil) Revenue, Net Income and Gross profit
  • Figure 26. Can-Fite BioPharma Ltd (Israil) Revenue: by Geography 2023
  • Figure 27. Regenacy Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 28. Regenacy Pharmaceuticals, LLC (United States) Revenue: by Geography 2023
  • Figure 29. MAKScientific (United States) Revenue, Net Income and Gross profit
  • Figure 30. MAKScientific (United States) Revenue: by Geography 2023
  • Figure 31. Metys Pharmaceuticals AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Metys Pharmaceuticals AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment: by Type USD Million (2024-2029)
  • Figure 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment: by Application USD Million (2024-2029)
  • Figure 35. South America Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 36. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 37. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 38. MEA Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
  • Figure 39. North America Chemotherapy Induced Peripheral Neuropathy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Achelios Therapeutics Inc (United States)
  • Advinus Therapeutics Limited (India)
  • Apollo Endosurgery Inc (United States)
  • Aptinyx Inc (United States)
  • Asahi Kasei Pharma Corp (Japan)
  • Can-Fite BioPharma Ltd (Israil)
  • Regenacy Pharmaceuticals, LLC (United States)
  • MAKScientific (United States)
  • Metys Pharmaceuticals AG (Switzerland)
Additional players considered in the study are as follows:
Nemus Bioscience (United States) , PledPharma (Sweden) , Sova Pharmaceuticals, Inc. (United States , DermaXon LLC (United States) , Immune Pharmaceuticals Inc. (United States) , Kineta, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 244 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Chemotherapy Induced Peripheral Neuropathy Treatment Quantitative research analysis
Chemotherapy Induced Peripheral Neuropathy Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Achelios Therapeutics Inc (United States), Advinus Therapeutics Limited (India), Apollo Endosurgery Inc (United States), Aptinyx Inc (United States), Asahi Kasei Pharma Corp (Japan), Can-Fite BioPharma Ltd (Israil), Regenacy Pharmaceuticals, LLC (United States), MAKScientific (United States) and Metys Pharmaceuticals AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Demand for Dose Reduction or Discontinuation of Treatment " is seen as one of major influencing trends for Chemotherapy Induced Peripheral Neuropathy Treatment Market during projected period 2023-2029.
The Chemotherapy Induced Peripheral Neuropathy Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Chemotherapy Induced Peripheral Neuropathy Treatment Report?

Have a Query? Click Here

Other Related Reports

Animal Therapeutics and Diagnostics Comprehensive Study by Type (Animal Diagnostics Products (Instruments, Consumables), Animal Therapeutics Products (Anti-Parasitic Drugs and Antibiotics, Anti-Infla...
$ 3750
Irritable Bowel Syndrome Treatment Comprehensive Study by Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride, Others), Distribution Channel (Hospital Pharmacies, Online...
$ 3450
Cancer Test Comprehensive Study by Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), Application (Bladder Cancer Test, Breast Cancer Test, Cervical Cancer Test, Colorectal (Colon) Cancer Te...
$ 3650
Dermatological Therapeutics Comprehensive Study by Type (Anti-infectives , Corticosteroids, Anti Psoriasis, Anti-acne , Others), Application (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopec...
$ 3750
Thyroid Cancer Treatment Comprehensive Study by Type (Surgery, Iodine Therapy, External Radiotherapy, Thyroxin Treatment, Chemotherapy, Drugs), Application (Hospitals, Oncology centers, Hospital Phar...
$ 3650
Urinary Tract Cancer Comprehensive Study by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Others), Diagnosis Technique (Cytoscopy, Urine Analyses, Biopsy, Imaging Test (Compute...
$ 3750